María Paniagua García*,Inmaculada López Hernández,Felipe Fernández Cuenca,María José Rios Villegas
Up until now, few cases of HBV reactivation after HCV therapy with new direct acting antivirals have been communicated, the majority of them without clinical repercussion. We present a case of fulminant hepatic failure for HBV reactivation in a patient infected with human immunodeficiency virus, after HCV therapy with DAAs.